Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thu-Oanh Dang

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Expert Review of Anticancer Therapy|November 22, 2015
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancerThu Oanh Dang, Adebayo Ogunniyi, Meagan S Barbee, et al.
The Annals of Pharmacotherapy|May 21, 2015
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncologyMeagan S Barbee, Adebayo Ogunniyi, Troy Z Horvat, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 3, 2020
Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare teamRobert J Ignoffo, Katherine K Knapp, Amy Seung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Expert Review of Anticancer Therapy|November 22, 2015
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancerThu Oanh Dang, Adebayo Ogunniyi, Meagan S Barbee, et al.
The Annals of Pharmacotherapy|May 21, 2015
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncologyMeagan S Barbee, Adebayo Ogunniyi, Troy Z Horvat, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 3, 2020
Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare teamRobert J Ignoffo, Katherine K Knapp, Amy Seung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Pageof 1